Suppliers

August 2012

Mystic gets additional patents for intranasal technology

Mystic Pharmaceuticals has announced that it has received a notice of allowance from the China Patent Office for a patent application titled “Deep Draw Container Forming Method” (invention number ZL200880106965.1). The company also said that… Read more . . .
Malvern Instruments acquires NanoSight

Particle characterization company Malvern Instruments has announced its acquisition of UK-based nanoparticle characterization specialist NanoSight. NanoSight’s instruments can analyze particle size, concentration, zeta potential, and aggregation of nanoparticles. Malvern Instruments Managing Director Paul Walker comented,… Read more . . .
Transcept licenses intranasal DHE

Transcept Pharmaceuticals has acquired global development and commercialization rights to Shin Nippon Biomedical Laboratories’ TO-2070 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the companies announced. Transcept will pay $1 million up front plus… Read more . . .
Positive results in artificial pancreas plus inhaled insulin study

Diabetes research organization JDRF, along with Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) have announced positive results from a trial of an artificial pancreas used in… Read more . . .
European approval for Ultibro Breezhaler

Just days after its approval in Japan, Novartis has announced that the Ultibro Breezhaler indacaterol/glycopyrronium (QVA149) DPI has been approved in Europe for the treatment of COPD. The approval triggers $10 million milestone payments to… Read more . . .
Positive opinion on Fluenz Tetra from CHMP

According to AstraZeneca, it has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its Fluenz Tetra intranasal four-strain live attenuated influenza vaccine developed by its MedImmune subsidiary.… Read more . . .
Avanir publishes data on intranasal sumatriptan

Avanir Pharmaceuticals has published results of a pharmacokinetic study of its AVP-825 intranasal sumatriptan powder for the treatment of acute migraine. Avanir licensed AVP-825 from OptiNose in July 2013, and the powder is delivered using… Read more . . .
Ultibro inhalation capsules approved in Japan

Sosei Group and Vectura have announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Ultibro glycopyrronium/indacaterol inhalation capsules, which are delivered using the Breezhaler DPI, for treatment of COPD. Ultibro, also… Read more . . .
Relvar Ellipta recommended for approval by CHMP, approved in Japan

GlaxoSmithKline and Theravance have announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of asthma… Read more . . .
Mundipharma launches Flutiform trial for COPD

A Phase 3 trial of Flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of COPD has been initiated, according Mundipharma. The 52-week randomized, double-blind EFFECT study compare Flutiform 250/10 μg and Flutiform 125/5 μg with… Read more . . .

Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan

September 15-September 18: DDL New Researcher Network Summer Event, London, UK

September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK

October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA

See all upcoming events

Suppliers